In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
We evaluated the in vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia using a susceptible strain and one with low-level resistance (MIC/MBC of levofloxacin: 0.06/0.06 and 4/4 mg/L, respectively). As demonstrated previously with other pathogens, the AUC/MIC ratio predicted the efficacy of fluoroquinolones against A. baumannii. This parameter correlated with bactericidal effect and survival. Combination therapy did not enhance the efficacy of levofloxacin.
Joly-Guillou
M L
ML
Service de Microbiologie, Hôpital Louis Mourier, 92701 Colombes, France.
Wolff
M
M
Farinotti
R
R
Bryskier
A
A
Carbon
C
C
D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D000583:Amikacin / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019540:Area Under Curve; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D015378:Imipenem / Q000627:therapeutic use; D064704:Levofloxacin; D051379:Mice; D008809:Mice, Inbred C3H; D008826:Microbial Sensitivity Tests / Q000379:methods; D015242:Ofloxacin / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013845:Thienamycins / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D013845:Thienamycins; D064704:Levofloxacin; D015378:Imipenem; D000583:Amikacin; D015242:Ofloxacin